
Michael Engelbert, MD, PhD, discusses how personalized faricimab dosing shows promise in extending dosing intervals for patients with wet age-related macular degeneration, which can enhance long-term treatment outcomes and patient adherence.


Michael Engelbert, MD, PhD, discusses how personalized faricimab dosing shows promise in extending dosing intervals for patients with wet age-related macular degeneration, which can enhance long-term treatment outcomes and patient adherence.

The meeting, being held from October 11-14 in New York City, will feature 4 presentations from ophthalmologists of the New York Eye and Ear Infirmary of Mount Sinai.

Visual acuity changes and conversion to neovascular AMD determined over 3 years in large patient cohort.

New data, insights on clinical trials, and perspective from researchers will be among the information shared at the 56th annual Retina Society congress being held in New York.